Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX)

$2.03 -0.17 (-7.73 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$2.03
Today's Range$2.00 - $2.28
52-Week Range$2.00 - $22.20
Volume205,567 shs
Average Volume196,916 shs
Market Capitalization$25.91 million
P/E RatioN/A
Dividend YieldN/A
Beta-9

About Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics logoAkari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKTX
CUSIPN/A
Phone44-20-8004-0270

Debt

Debt-to-Equity RatioN/A
Current Ratio2.38%
Quick Ratio2.38%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book0.70

Profitability

Trailing EPS($0.28)
Net Income$-18,140,000.00
Net MarginsN/A
Return on Equity-152.12%
Return on Assets-102.69%

Miscellaneous

Employees15
Outstanding Shares11,780,000

Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

When will Akari Therapeutics make its next earnings announcement?

Akari Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for Akari Therapeutics.

Where is Akari Therapeutics' stock going? Where will Akari Therapeutics' stock price be in 2018?

4 Wall Street analysts have issued 12 month price targets for Akari Therapeutics' shares. Their predictions range from $2.50 to $15.00. On average, they expect Akari Therapeutics' share price to reach $6.83 in the next twelve months. View Analyst Ratings for Akari Therapeutics.

What are Wall Street analysts saying about Akari Therapeutics stock?

Here are some recent quotes from research analysts about Akari Therapeutics stock:

  • 1. According to Zacks Investment Research, "Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. " (1/16/2018)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline." (9/22/2017)
  • 3. Chardan Capital analysts commented, "We are very proud of the continued advancement of our Coversin program for the treatment of PNH in patients with or without polymorphisms," Gur Roshwalb, CEO of Akari Therapeutics said in a press release. "The FDA fast track designation recognizes the unmet need in patients with PNH who cannot be treated with the current standard of care due to polymorphisms."Not So FastKumar pointed out a 2014 study, which found that only 3.2 percent of PNH patients had Soliris resistance mutations. Moreover, for a disease with an incidence rate of 1.3 per million, Soliris-resistant PNH represents just 10 to 20 patients in the US per year.As such, the analyst emphasized that Akari's designation represents "an extremely limited subset of PNH patients" (4/17/2017)

Who are some of Akari Therapeutics' key competitors?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the folowing people:

  • Ray Prudo M.D., Chairman of the Board
  • David Horn Solomon, Chief Executive Officer (Age 57)
  • Dov Elefant, Chief Financial Officer (Age 47)
  • Clive Richardson, Chief Operating Officer, Director
  • Nigel A.S. Hernandez Ph.D., Vice President - Worldwide Regulatory Affairs
  • David Byrne, Director
  • Peter Feldschreiber, Director
  • Michael Grissinger, Director
  • Robert E. Ward, Director (Age 60)
  • Donald A. Williams, Director (Age 57)

Who owns Akari Therapeutics stock?

Akari Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include AWM Investment Company Inc. (5.81%), Millennium Management LLC (2.21%) and Endurant Capital Management LP (1.71%). View Institutional Ownership Trends for Akari Therapeutics.

Who bought Akari Therapeutics stock? Who is buying Akari Therapeutics stock?

Akari Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Endurant Capital Management LP and Millennium Management LLC. View Insider Buying and Selling for Akari Therapeutics.

How do I buy Akari Therapeutics stock?

Shares of Akari Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of Akari Therapeutics stock can currently be purchased for approximately $2.03.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $25.91 million. The biopharmaceutical company earns $-18,140,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Akari Therapeutics employs 15 workers across the globe.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 44-20-8004-0270 or via email at [email protected]


MarketBeat Community Rating for Akari Therapeutics (AKTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akari Therapeutics (NASDAQ:AKTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.83$8.75$8.75$8.75
Price Target Upside: 212.02% upside6.97% upside6.97% upside141.71% upside

Akari Therapeutics (NASDAQ:AKTX) Consensus Price Target History

Price Target History for Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics (NASDAQ:AKTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018B. RileyInitiated CoverageNeutral -> Neutral$3.00HighView Rating Details
9/22/2017Canaccord GenuityReiterated RatingBuy$15.00LowView Rating Details
9/22/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/17/2017Chardan CapitalReiterated RatingNeutralLowView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Akari Therapeutics (NASDAQ:AKTX) Earnings History and Estimates Chart

Earnings by Quarter for Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics (NASDAQ AKTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2018        
11/13/2017Q3 2017($1.00)($0.09)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.70)($0.06)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.54)($0.09)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.08)ViewN/AView Earnings Details
11/10/2016Q3 2016$0.03ViewN/AView Earnings Details
8/11/2016Q2 2016($0.45)ViewN/AView Earnings Details
11/23/2015Q3 2015($0.03)ViewN/AView Earnings Details
1/7/2014Q4 2012($1.90)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Akari Therapeutics (NASDAQ:AKTX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.01)($0.01)($0.01)
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.01)($0.01)($0.01)
Q4 20181($0.01)($0.01)($0.01)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Akari Therapeutics (NASDAQ:AKTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Akari Therapeutics (NASDAQ AKTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 61.80%
Institutional Ownership Percentage: 27.16%
Insider Trades by Quarter for Akari Therapeutics (NASDAQ:AKTX)
Institutional Ownership by Quarter for Akari Therapeutics (NASDAQ:AKTX)

Akari Therapeutics (NASDAQ AKTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2015Mark S CohenDirectorBuy1,055,600$0.19$200,564.001,055,600View SEC Filing  
4/15/2014Sabby Management, LlcMajor ShareholderBuy20,100$5.03$101,103.00View SEC Filing  
4/11/2014Sabby Management, LlcMajor ShareholderBuy2,575$5.35$13,776.25View SEC Filing  
4/8/2014Sabby Management, LlcMajor ShareholderBuy68,404$5.59$382,378.36View SEC Filing  
4/2/2014Sabby Management, LlcMajor ShareholderBuy28,207$6.22$175,447.54View SEC Filing  
3/27/2014Sabby Management, LlcMajor ShareholderBuy16,203$6.66$107,911.98View SEC Filing  
3/24/2014Sabby Management, LlcMajor ShareholderBuy11,100$6.83$75,813.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akari Therapeutics (NASDAQ AKTX) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$1.00 Per ShareZacks: Brokerages Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$1.00 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Akari Therapeutics PLC Forecasted to Earn FY2017 Earnings of ($3.00) Per Share (AKTX)Akari Therapeutics PLC Forecasted to Earn FY2017 Earnings of ($3.00) Per Share (AKTX)
www.americanbankingnews.com - February 12 at 1:08 AM
Akari Therapeutics (AKTX) Coverage Initiated at B. RileyAkari Therapeutics (AKTX) Coverage Initiated at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Akari Therapeutics PLC (AKTX) Given Consensus Recommendation of "Hold" by BrokeragesAkari Therapeutics PLC (AKTX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 8 at 11:50 AM
Akari Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceAkari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 8 at 8:55 AM
Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical TrialsAkari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials
finance.yahoo.com - February 6 at 9:07 AM
Head to Head Contrast: Kura Oncology (KURA) and Akari Therapeutics (AKTX)Head to Head Contrast: Kura Oncology (KURA) and Akari Therapeutics (AKTX)
www.americanbankingnews.com - February 1 at 9:12 PM
 Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share Analysts Expect Akari Therapeutics PLC (AKTX) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - January 29 at 3:14 AM
Akari Therapeutics Strengthens Board with Two Senior Industry AppointmentsAkari Therapeutics Strengthens Board with Two Senior Industry Appointments
finance.yahoo.com - January 23 at 8:19 AM
 Brokerages Set $2.50 Target Price for Akari Therapeutics PLC (AKTX) Brokerages Set $2.50 Target Price for Akari Therapeutics PLC (AKTX)
www.americanbankingnews.com - January 22 at 3:36 PM
Akari Therapeutics (AKTX) Stock Rating Lowered by Zacks Investment ResearchAkari Therapeutics (AKTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
Zacks: Akari Therapeutics PLC (AKTX) Given Consensus Rating of "Buy" by AnalystsZacks: Akari Therapeutics PLC (AKTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 13 at 5:34 PM
Akari Therapeutics PLC (AKTX) Expected to Post Earnings of -$1.00 Per ShareAkari Therapeutics PLC (AKTX) Expected to Post Earnings of -$1.00 Per Share
www.americanbankingnews.com - January 12 at 5:14 AM
Penumbra (PEN) Forms JV on Virtual Reality in Health Space ... - NasdaqPenumbra (PEN) Forms JV on Virtual Reality in Health Space ... - Nasdaq
www.nasdaq.com - January 6 at 5:43 AM
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy - NasdaqAnika Therapeutics Receives FDA Nod for Bone Repair Therapy - Nasdaq
www.nasdaq.com - January 5 at 2:10 PM
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments - NasdaqThermo Fisher Buys Phenom-World, Aids Analytical Instruments - Nasdaq
www.nasdaq.com - January 5 at 2:10 PM
Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%
finance.yahoo.com - January 5 at 2:10 PM
New Products Aid Boston Scientific, LOTUS Relaunch Lag AilsNew Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
www.zacks.com - January 3 at 3:51 PM
Zacks: Akari Therapeutics PLC (AKTX) Given $2.50 Consensus Price Target by AnalystsZacks: Akari Therapeutics PLC (AKTX) Given $2.50 Consensus Price Target by Analysts
www.americanbankingnews.com - December 29 at 5:52 AM
Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in SessionArray BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session
finance.yahoo.com - December 26 at 12:11 PM
Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% HigherAmarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher
finance.yahoo.com - December 21 at 11:07 AM
Zacks: Akari Therapeutics PLC (AKTX) Receives Average Recommendation of "Buy" from BrokeragesZacks: Akari Therapeutics PLC (AKTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 14 at 5:40 PM
Tenet Healthcare (THC) in Focus: Stock Moves 8.5% HigherTenet Healthcare (THC) in Focus: Stock Moves 8.5% Higher
finance.yahoo.com - December 13 at 11:31 AM
Alexion (ALXN) in Focus: Stock Moves 7.2% HigherAlexion (ALXN) in Focus: Stock Moves 7.2% Higher
finance.yahoo.com - December 11 at 11:50 AM
Akari Therapeutics (AKTX) and Sarepta Therapeutics (SRPT) Financial ComparisonAkari Therapeutics (AKTX) and Sarepta Therapeutics (SRPT) Financial Comparison
www.americanbankingnews.com - December 5 at 9:32 PM
Akari: December Coversin Update, Analysts Opinion and CatalystsAkari: December Coversin Update, Analysts Opinion and Catalysts
finance.yahoo.com - December 2 at 3:49 PM
Akari Therapeutics (AKTX) Upgraded by ValuEngine to SellAkari Therapeutics (AKTX) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - November 30 at 11:02 PM
Brokerages Anticipate Akari Therapeutics PLC (AKTX) to Announce ($1.00) Earnings Per ShareBrokerages Anticipate Akari Therapeutics PLC (AKTX) to Announce ($1.00) Earnings Per Share
www.americanbankingnews.com - November 28 at 8:02 AM
ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%
finance.yahoo.com - November 27 at 10:18 AM
Zacks: Brokerages Expect Akari Therapeutics PLC (AKTX) to Announce -$1.00 EPSZacks: Brokerages Expect Akari Therapeutics PLC (AKTX) to Announce -$1.00 EPS
www.americanbankingnews.com - November 21 at 3:26 AM
European ADRs Inch Higher in Monday SessionEuropean ADRs Inch Higher in Monday Session
www.nasdaq.com - November 20 at 3:21 PM
FY2017 Earnings Estimate for Akari Therapeutics PLC Issued By William Blair (AKTX)FY2017 Earnings Estimate for Akari Therapeutics PLC Issued By William Blair (AKTX)
www.americanbankingnews.com - November 17 at 9:44 PM
Akari Therapeutics PLC (AKTX) Upgraded at Zacks Investment ResearchAkari Therapeutics PLC (AKTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
 Akari Therapeutics PLC (AKTX) Given Average Rating of "Buy" by Analysts Akari Therapeutics PLC (AKTX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 3:03 PM
Comparing Akari Therapeutics PLC (AKTX) and The CompetitionComparing Akari Therapeutics PLC (AKTX) and The Competition
www.americanbankingnews.com - November 8 at 9:34 PM
Analyzing Akari Therapeutics PLC (AKTX) and The CompetitionAnalyzing Akari Therapeutics PLC (AKTX) and The Competition
www.americanbankingnews.com - October 31 at 11:10 PM
Akari Therapeutcis (AKTX) Prices 3.48M ADS Offering at $5/ShAkari Therapeutcis (AKTX) Prices 3.48M ADS Offering at $5/Sh
www.streetinsider.com - October 19 at 4:15 PM
Akari Therapeutics Announces Pricing of Public Offering of American Depositary SharesAkari Therapeutics Announces Pricing of Public Offering of American Depositary Shares
finance.yahoo.com - October 18 at 4:54 PM
Zacks Investment Research Lowers Akari Therapeutics PLC (AKTX) to SellZacks Investment Research Lowers Akari Therapeutics PLC (AKTX) to Sell
www.americanbankingnews.com - October 17 at 9:02 PM
Akari Therapeutics Announces Proposed Public Offering of American Depositary SharesAkari Therapeutics Announces Proposed Public Offering of American Depositary Shares
finance.yahoo.com - October 17 at 4:35 PM
Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)
finance.yahoo.com - October 13 at 3:38 PM
 Brokerages Expect Akari Therapeutics PLC (AKTX) Will Post Earnings of -$1.00 Per Share Brokerages Expect Akari Therapeutics PLC (AKTX) Will Post Earnings of -$1.00 Per Share
www.americanbankingnews.com - October 12 at 4:20 PM
Akari Therapeutics Announces Further Clinical ProgressAkari Therapeutics Announces Further Clinical Progress
finance.yahoo.com - October 11 at 5:15 PM
Akari Therapeutics PLC (AKTX) Expected to Announce Earnings of -$0.77 Per ShareAkari Therapeutics PLC (AKTX) Expected to Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - September 24 at 12:18 AM
Akari Therapeutics PLC (AKTX) Receives Buy Rating from Canaccord GenuityAkari Therapeutics PLC (AKTX) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 22 at 9:38 PM
Akari Therapeutics Announces Regulatory Progress Following FDA MeetingAkari Therapeutics Announces Regulatory Progress Following FDA Meeting
finance.yahoo.com - September 22 at 7:50 PM
Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's WhyAkari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why
finance.yahoo.com - September 22 at 7:50 PM
Akari Therapeutics Rally Continues As William Blair UpgradesAkari Therapeutics Rally Continues As William Blair Upgrades
finance.yahoo.com - September 22 at 7:50 PM
Akari Therapeutics PLC (AKTX) Raised to "Outperform" at William BlairAkari Therapeutics PLC (AKTX) Raised to "Outperform" at William Blair
www.americanbankingnews.com - September 22 at 9:18 AM
Akari Therapeutics PLC (AKTX) Given Neutral Rating at Chardan CapitalAkari Therapeutics PLC (AKTX) Given Neutral Rating at Chardan Capital
www.americanbankingnews.com - September 20 at 6:26 AM

SEC Filings

Akari Therapeutics (NASDAQ:AKTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akari Therapeutics (NASDAQ:AKTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akari Therapeutics (NASDAQ AKTX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.